Abstract
Eighty two eligible children with 'standard risk' lymphoblastic leukaemia were entered into the Medical Research Council UKALL VII trial. Three failed to remit. With a minimum follow up time of four years, actuarial relapse free survival for the remainder was 65%; a significant improvement over the two preceding 'standard risk' trials at the same stage. Only one of five treatment variables possibly affected relapse free survival; this being whether methotrexate was given orally or parenterally during remission maintenance treatment. Twenty seven of 36 patients (75%) who were given intramuscular methotrexate remain alive and in their first remission compared with 23 of 41 (56%) given the drug orally. Although statistically significant differences in small trials should be interpreted with caution, this finding raises the possibility that orally administered methotrexate is not completely absorbed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Herber S., Lennard L., Lilleyman J. S., Maddocks J. 6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia. Br J Cancer. 1982 Jul;46(1):138–141. doi: 10.1038/bjc.1982.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kearney P. J., Light P. A., Preece A., Mott M. G. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1979;3(2):117–120. doi: 10.1007/BF00254982. [DOI] [PubMed] [Google Scholar]
- Pinkerton C. R., Welshman S. G., Glasgow J. F., Bridges J. M. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet. 1980 Nov 1;2(8201):944–946. doi: 10.1016/s0140-6736(80)92105-4. [DOI] [PubMed] [Google Scholar]
- Smith S. D., Rosen D., Trueworthy R. C., Lowman J. T. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979 Jan;43(1):169–173. doi: 10.1002/1097-0142(197901)43:1<169::aid-cncr2820430125>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Zimm S., Collins J. M., Riccardi R., O'Neill D., Narang P. K., Chabner B., Poplack D. G. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med. 1983 Apr 28;308(17):1005–1009. doi: 10.1056/NEJM198304283081705. [DOI] [PubMed] [Google Scholar]